News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,916 Results
Type
Article (40024)
Company Profile (250)
Press Release (664641)
Multimedia
Podcasts (61)
Webinars (14)
Section
Business (204282)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81148)
Employer Resources (172)
FDA (16249)
Job Trends (14887)
News (345513)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1444)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2870)
Cardiovascular disease (213)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66863)
Collaboration (1014)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2626)
CRISPR (56)
C-suite (329)
Cystic fibrosis (112)
Data (3002)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6424)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (126)
Earnings (87457)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113745)
Executive appointments (845)
FDA (17902)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (374)
GLP-1 (787)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (9)
Indications (39)
Infectious disease (2798)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (91)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19583)
Metabolic disorders (852)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2121)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (431)
Opinion (217)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (299)
Patient recruitment (166)
Peanut (50)
People (57690)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20832)
Phase II (29452)
Phase III (21920)
Pipeline (1637)
Policy (200)
Postmarket research (2563)
Preclinical (8872)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (458)
Real estate (5917)
Recruiting (66)
Regulatory (22637)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (39)
Vaccines (781)
Venture capital (54)
Weight loss (258)
Women's health (47)
Worklife (16)
Date
Today (78)
Last 7 days (347)
Last 30 days (1819)
Last 365 days (31187)
2025 (16806)
2024 (35221)
2023 (40077)
2022 (51173)
2021 (55713)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38214)
Australia (6232)
California (7441)
Canada (2360)
China (671)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82111)
Florida (1118)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (637)
India (27)
Indiana (361)
Iowa (16)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1023)
Massachusetts (5529)
Michigan (246)
Minnesota (450)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2080)
New Mexico (28)
New York (2085)
North Carolina (1080)
North Dakota (8)
Northern California (3277)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1612)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2784)
Tennessee (126)
Texas (1126)
United States (27576)
Utah (220)
Virginia (185)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
704,916 Results for "altimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout.
June 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Altimmune to Participate in the Citizens Life Sciences Conference
April 30, 2025
·
1 min read
Press Releases
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
June 16, 2025
·
3 min read
Press Releases
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
July 10, 2025
·
6 min read
Press Releases
Altimmune to Participate at Two Upcoming Investor Conferences - May 14, 2025
May 15, 2025
·
1 min read
Press Releases
Altimmune Announces First Quarter 2025 Financial Results and Business Update
May 14, 2025
·
10 min read
Press Releases
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
May 2, 2025
·
2 min read
Press Releases
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
June 26, 2025
·
12 min read
Press Releases
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
June 26, 2025
·
5 min read
Press Releases
Altimmune to Participate in the Leerink Global Healthcare Conference
March 4, 2025
·
1 min read
1 of 70,492
Next
